secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2026-09-21T20:34:25+00:00
Accession:  0001070081-26-000023
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC completes acquisition of ST-920 Fabry gene therapy from Sangamo; BLA submission expected Q4 2026
--------------------------------------------------------------------------------

- Completed acquisition of ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics.
- Rolling BLA submission to FDA for accelerated approval expected to be completed in Q4 2026.
- BLA based on 52-week Phase 1/2 STAAR study showing favorable renal function effect and safety/tolerability.
- Company also plans to pursue regulatory approval of ST-920 outside the United States.
- CEO Matthew Klein cites potential to address limitations of chronic enzyme replacement therapy for Fabry community.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000023/0001070081-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008126000023/tmb-20260921x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer